News

Filter

151 to 160 of 97199 results

AstraZeneca wins in US Nexium pay-for-delay litigation

AstraZeneca wins in US Nexium pay-for-delay litigation

07-12-2014

Anglo-Swedish pharma major AstraZeneca revealed on Friday that a jury in the US District Court for the…

AstraZenecaGastro-intestinalsGenericsLegalNexiumPatentsRanbaxyUSA

Orexo presents new Ph III data for Zubsolv

07-12-2014

The US subsidiary of Swedish drug developer Orexo says that, in the ISTART Phase III study, Zubsolv (buprenorphine…

NeurologicalOrexoPharmaceuticalResearchSuboxoneZubsolv

Bayer files for European approval of hemophilia A drug BAY 81-8973

06-12-2014

German pharma major Bayer has filed an application for marketing authorization to the European Medicines…

BAY 81-8973BayerEuropeHematologyPharmaceuticalRegulation

FDA advisory panel backs Actavis’ ceftazidime-avibactam

06-12-2014

Ireland-headquartered generic drugs major Actavis says that the Anti-Infective Drugs Advisory Committee…

ActavisAntibiotics and Infectious diseasesAstraZenecaceftazidime-avibactamPharmaceuticalRegulationUSA

EMA update on review of studies performed at GVK Biosciences site in Hyderabad, India

06-12-2014

Some European Union member states have decided to suspend the marketing authorizations of medicines that…

EuropeGVK BiosciencesIndiaPharmaceuticalRegulationResearch

Turning a constraint into an enabler: transparency round-table at Veeva's commercial summit 2014

Turning a constraint into an enabler: transparency round-table at Veeva's commercial summit 2014

05-12-2014

In one of the opening sessions, cloud-based life sciences provider Veeva’s co-founder and president…

BMI SystemEuropeInterviewsPharmaceuticalRegulationVeeva

Mixed findings from IQWiG on added benefit for Eliquis

05-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined a dossier on Eliquis…

Bristol-Myers SquibbCardio-vascularEliquisGermanyPfizerPharmaceuticalPricingRegulation

Patient access to novel non-insulin treatments is sub-optimal in China

05-12-2014

With respect to the treatment of type 2 diabetes in China, patient access to premium-priced agents is…

AstraZenecaByettaChinaDiabetesHealthcareJanuviaMarkets & MarketingMerck & CoPharmaceutical

Takeda receives Breakthrough designation for ixazomib

Takeda receives Breakthrough designation for ixazomib

05-12-2014

Japanese drug major Takeda Pharmaceutical’s has been granted Breakthrough Therapy designation from…

ixazomibPharmaceuticalRare diseasesRegulationTakeda PharmaUSA

151 to 160 of 97199 results

Back to top